Photo by nci from unsplash
Over the past 20 years, the regulatory approval of several novel agents to treat multiple myeloma (MM) has prolonged median patient survival from 3 to 8-10 years. Increased understanding of… Click to show full abstract
Over the past 20 years, the regulatory approval of several novel agents to treat multiple myeloma (MM) has prolonged median patient survival from 3 to 8-10 years. Increased understanding of MM biology has translated to advances in diagnosis, prognosis, and response assessment, as well as informed the development of targeted and immune agents. Here we provide an overview of the recent progress in MM, and highlight research areas of greatest promise to further improve patient outcome in the future.
Keywords:
myeloma;
multiple myeloma;
therapy glance;
current therapy;
myeloma evolution;
evolution current
Journal Title: Haematologica
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Haematologica
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!